Literature DB >> 19097181

Health-related quality of life in Huntington's disease: Which factors matter most?

Aileen K Ho1, Abigail S Gilbert, Sarah L Mason, Anna O Goodman, Roger A Barker.   

Abstract

The aim of this article was to determine which aspects of Huntington's disease (HD) are most important with regard to the health-related quality of life (HrQOL) of patients with this neurodegenerative disease. Seventy patients with HD participated in the study. Assessment comprised the Unified Huntington's Disease Rating Scale (UHDRS) motor, cognitive and functional capacity sections, and the Beck Depression inventory. Mental and physical HrQOL were assessed using summary scores of the SF-36. Multiple regression analyses showed that functional capacity and depressive mood were significantly associated with HrQOL, in that greater impairments in HrQOL were associated with higher levels of depressive mood and lower functional capacity. Motor symptoms and cognitive function were not found to be as closely linked with HrQOL. Therefore, it can be concluded that, depressive mood and greater functional incapacity are key factors in HrQOL for people with HD, and further longitudinal investigation will be useful to determine their utility as specific targets in intervention studies aimed at improving patient HrQOL, or whether other mediating variables. As these two factors had a similar association with the mental and physical summary scores of the SF-36, this generic HrQOL measure did not adequately capture and distinguish the true mental and physical health-related HrQOL in HD.

Entities:  

Mesh:

Year:  2009        PMID: 19097181     DOI: 10.1002/mds.22412

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

1.  Couples' coping in prodromal Huntington disease: a mixed methods study.

Authors:  Nancy R Downing; Janet K Williams; Anne L Leserman; Jane S Paulsen
Journal:  J Genet Couns       Date:  2012-01-26       Impact factor: 2.537

2.  Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias.

Authors:  Heike Jacobi; Sophie Tezenas du Montcel; Peter Bauer; Paola Giunti; Arron Cook; Robyn Labrum; Michael H Parkinson; Alexandra Durr; Alexis Brice; Perrine Charles; Cecilia Marelli; Caterina Mariotti; Lorenzo Nanetti; Lidia Sarro; Maria Rakowicz; Anna Sulek; Anna Sobanska; Tanja Schmitz-Hübsch; Ludger Schöls; Holger Hengel; Laszlo Baliko; Bela Melegh; Alessandro Filla; Antonella Antenora; Jon Infante; José Berciano; Bart P van de Warrenburg; Dagmar Timmann; Sandra Szymanski; Sylvia Boesch; Wolfgang Nachbauer; Jun-Suk Kang; Massimo Pandolfo; Jörg B Schulz; Audrey Tanguy Melac; Alhassane Diallo; Thomas Klockgether
Journal:  J Neurol       Date:  2018-06-29       Impact factor: 4.849

3.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

4.  Perceived stress in prodromal Huntington disease.

Authors:  Nancy Downing; Megan M Smith; Leigh J Beglinger; James Mills; Kevin Duff; Kelly C Rowe; Eric Epping; Jane S Paulsen
Journal:  Psychol Health       Date:  2011-06-21

5.  Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Yaroslav Winter; Karsten Schepelmann; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Björn Tackenberg; Veit Mylius; Jens-Peter Reese; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 6.  Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.

Authors:  Deepa Dash; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

7.  Does pallidal neuromodulation influence cognitive decline in Huntington's disease?

Authors:  Emily Sanrey; Valérie Macioce; Victoria Gonzalez; Laura Cif; Fabienne Cyprien; Emilie Chan Seng; Philippe Coubes; Gaetan Poulen
Journal:  J Neurol       Date:  2020-09-04       Impact factor: 4.849

8.  Understanding the need for assistance with survey completion in people with Huntington disease.

Authors:  Elizabeth A Hahn; Nancy R Downing; Julie C Stout; Jane S Paulsen; Becky Ready; Siera Goodnight; Jin-Shei Lai; Jennifer A Miner; Noelle E Carlozzi
Journal:  Qual Life Res       Date:  2017-12-06       Impact factor: 4.147

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

10.  Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease.

Authors:  Nora E Fritz; Nicholas R Boileau; Julie C Stout; Rebecca Ready; Joel S Perlmutter; Jane S Paulsen; Kimberly Quaid; Stacey Barton; Michael K McCormack; Susan L Perlman; Noelle E Carlozzi
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2018-03-21       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.